One study showed that Notch-1 mutations constitutively activate the NF-κB signaling pathway in CLL (chronic lymphocytic leukemia), and indicating Notch1 and NF-κB could be as potential therapeutic targets in the treatment of CLL [23]. This evidence concerns the gene NFKB1 and B-cell chronic lymphocytic leukemia.